Valsartan
|
|
|
- CAS-Nr.
- 137862-53-4
- Englisch Name:
- Valsartan
- Synonyma:
- DIOVAN;Nisis;Valsratan;Varsartan;Tareg;CGP-48933;VALSARTAN;Valsatarn;Valsartane;L-Valsartan
- CBNumber:
- CB6182539
- Summenformel:
- C24H29N5O3
- Molgewicht:
- 435.52
- MOL-Datei:
- 137862-53-4.mol
|
Valsartan Eigenschaften
- Schmelzpunkt:
- 116-117°C
- Siedepunkt:
- 684.9±65.0 °C(Predicted)
- Dichte
- 1.212±0.06 g/cm3(Predicted)
- Dampfdruck
- 0-0Pa at 20-25℃
- storage temp.
- 2-8°C
- Löslichkeit
- DMSO: ≥20mg/mL
- Aggregatzustand
- powder
- pka
- 3.56±0.10(Predicted)
- Farbe
- white to tan
- Optische Aktivität
- [α]/D -55 to -70°, c = 1 in methanol
- Wasserlöslichkeit
- 84.99mg/L(25 ºC)
- Merck
- 14,9916
- BCS Class
- 2
- Stabilität:
- Hygroscopic
- InChIKey
- ACWBQPMHZXGDFX-QFIPXVFZSA-N
- LogP
- 1.2-2.8 at 25℃ and pH2.5-7
- Oberflächenspannung
- 59.6-68.1mN/m at 10-100mg/L and 20℃
- Dissoziationskonstante
- 3.76-4.38 at 25℃
- CAS Datenbank
- 137862-53-4(CAS DataBase Reference)
- EPA chemische Informationen
- L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (137862-53-4)
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
 
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H336 |
Kann Schläfrigkeit und Benommenheit verursachen. |
Spezifische Zielorgan-Toxizität (einmalige Exposition) |
Kategorie 3 (Schläfrigkeit und Benommenheit) |
Warnung |
|
P261, P271, P304+P340, P312,P403+P233, P405, P501 |
|
| Sicherheit |
| P201 |
Vor Gebrauch besondere Anweisungen einholen. |
| P308+P313 |
BEI Exposition oder falls betroffen: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
|
Valsartan Chemische Eigenschaften,Einsatz,Produktion Methoden
R-Sätze Betriebsanweisung:
R36/37/38:Reizt die Augen, die Atmungsorgane und die Haut.
S-Sätze Betriebsanweisung:
S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
S37/39:Bei der Arbeit geeignete Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.
Beschreibung
Diovan(Valsartan) was launched in Germany and the UK as an angiotensin Ⅱ
antagonist for use as an antihypertensive agent. Biphenylbromomethyl nitrite serves
as the starting material for a three step synthesis of the compound, in which the (S)-
enantiomer is more active than the (R)-enantiomer. Valsartan is a nonpeptide drug
which is a highly specific antagonist of the AT
1 receptor and is potent and orally
active. This receptor is responsible for angiotensin Ⅱ cardiovascular effects
(aldosterone and catecholamine secretion, vascular constriction, positive inotropic
response and renal effects). Unlike losartan, it is not a prodrug and a single daily
dose is comparible in activity to the ACE drug enalapril. It also did not exhibit the
coughing side effect observed with ACE inhibitors. Diovan(Valsartan) is slowly metabolized
(long lasting) with its main metabolite being significantly less active. There was no
evidence of rebound hypertension when drug treatment was terminated and was as
effective as the dihydropyridine Ca antagonist anlodipine.
Chemische Eigenschaften
White Crystalline Powder
Definition
ChEBI: A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.
Allgemeine Beschreibung
Valsartan, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine (Diovan), likelosartan, possesses the acidic tetrazole system, which mostlikely plays a role, similar to that of the acidic groups of angiotensinII, in binding to the angiotensin II receptor. In addition,the biphenyl system that serves to separate the tetrazolefrom the aliphatic nitrogen is still present. In addition, there isa carboxylic acid side chain in the valine moiety that alsoserves to bind to the angiotensin II receptor.
Valsartan Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Valsartan Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 997)Lieferanten
137862-53-4()Verwandte Suche:
- L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
- Ambroxol Hydrochloride Imp.D
- 3-Methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]-butanoic aci
- (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]amine
- (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic aci
- VALSARTAN IMP C
- Valsartan,99%e.e.
- N-(1-OXOPENTYL)-N-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-L-VALINE
- VALSARTAN
- CGP-48933
- VALSARTAN, MM STANDARD
- VALSARTAN, USP STANDARD
- VALSARTAN, RELATED COMPOUND A(R)-N-VALERYL-N-([2'-(1-H-TETRAZOLE)-5-YL)-BIPHENYL-4-YL]-METHYL)-VALINE USP STANDARD
- VALSARTAN, RELATED COMPOUND C(S)-N-VALERYL-N-([2'-(1-H-TETRAZOLE)-5-YL)-BIPHENYL-4-YL]-METHYL)-VALINE BENZYL ESTER USP STANDARD
- Valsartan99%
- N-[[(2-Cyano(1.1-Biphenyl)-4-Yl)Methyl]MethylEster]-L-Valine.Hydrochloride
- ValsartanC24H29N503
- Valsartane
- (S)-2-(N-((2''-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)PENTANAMIDO)-3-METHYLBUTANOIC ACID
- Diovan, N-(1-Oxopentyl)-N-[[2(1H-tetrazol-5-yl)[1,1biphenyl]-4-yl]methyl]-L-valine, CGP-48933
- N-(1-N.PENTANOYL)-N-[[2''-(1H-TETRAZOL-5-YL)[1'',1- BIPHENYL]-4-YL]METHYL]-L-VALINE/VALSARTAN
- L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
- Tareg
- 3-methyl-2-[pentanoyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]amino]-butanoic acid
- Valsartan Related Compound A (10 mg) ((R)-N-Valeryl-N-([2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine)
- N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-
- N-(1-Oxopentyl)-N-[[2’-(1H-tetrazol-5-y1)[1，1'-biphenyl]-4-y1]methyl]-L-valine
- N-(1-Oxopentyl)-N-[[2'-(2H-tetrazo-5-yl)
- Valsartan (350 mg)G0F0650.997mg/mg(an)
- Valsartan (350 mg)
- 3-Methyl-2-[pentanoy
- L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
- (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)pentanaMido)-3-Methylbutanoic acid
- Valsartan API
- Valsartan (>99% pure)
- N-Valeryl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-L-valine
- (2S)-3-Methyl-2-[N-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}Methyl)pentanaMido]butanoic acid
- L-Valsartan
- 2-(N-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)pentanaMido)-3-Methylbutanoic acid
- ((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)-L-valine
- N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
(S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3 -methylbutanoic acid- (S)-N-[p-(o-1H-Tetrazol-5-ylphenyl)benzyl]-N-valeryl-L-valine
- (S)-2-(N-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid
- Valsartan, 99%, a nonpeptide angiotensin II AT1 receptor antagonist
- Valsartan 3-Methyl-2-[pentanoyl-[[4- [2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl] amino]-butanoic acid
- Valsartan Manufacturer
- (S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid
- Valsatarn
- Valsartan Impurity 18
- (S)-2-(N-((2'-(1H-tetrazol-5-yl)
- Valsartan CRS
- Valsartan RS
- Valsartan for peak identification CRS
- Valsartan for system suitability CRS
- N-Valeryl-N-[2'-(5-tetrazolyl)biphenyl-4-ylmethyl]-L-valine
- N-((2-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine
- Valsartan USP/EP/BP
